We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+18.77%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$5.81B
AUM Growth
+$81.2M
Cap. Flow
-$585M
Cap. Flow %
-10.08%
Top 10 Hldgs %
85.45%
Holding
128
New
20
Increased
23
Reduced
35
Closed
17

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.13M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.85M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.62M
4
PRQR icon
ProQR Therapeutics
PRQR
+$5.19M
5
ARRY
Array Biopharma Inc
ARRY
+$5.11M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.6M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$15M
3
ONC
BeOne Medicines Ltd
ONC
+$13M
4
BLUE
bluebird bio
BLUE
+$12.4M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M

Sector Composition

Rank Sector Weight
1 Consumer Staples 42.79%
2 Consumer Discretionary 22.09%
3 Healthcare 21.32%
4 Financials 0%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
51
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.76M 0.13%
250,000
– –
MDCO
52
CALL
DELISTED
Medicines Co
MDCO
$7.41M 0.13%
200,000
– –
PRQR icon
53
ProQR Therapeutics
PRQR
$261M
$7.28M 0.13%
1,500,000
+1,000,000
+200% +$5.19M
BLUE
54
CALL
DELISTED
bluebird bio
BLUE
$6.87M 0.12%
3,860
– –
JUNO
55
DELISTED
Juno Therapeutics, Inc.
JUNO
$6.73M 0.12%
150,000
-50,000
-25% -$1.7M
HZNP
56
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.34M 0.11%
500,000
– –
HZNP
57
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.34M 0.11%
500,000
-260,000
-34% -$3.31M
ALDR
58
DELISTED
Alder Biopharmaceuticals
ALDR
$6.13M 0.11%
500,000
+200,000
+67% +$2.09M
BOLD
59
DELISTED
Audentes Therapeutics, Inc
BOLD
$5.6M 0.1%
+200,000
New +$4.34M
ACIU icon
60
AC Immune
ACIU
$262M
$5.58M 0.1%
500,000
– –
SGEN
61
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$5.44M 0.09%
100,000
– –
RGNX icon
62
Regenxbio
RGNX
$704M
$5.27M 0.09%
160,000
– –
ANAB icon
63
AnaptysBio
ANAB
$1.66B
$5.24M 0.09%
150,000
-100,000
-40% -$2.7M
TGTX icon
64
TG Therapeutics
TGTX
$7.34B
$4.74M 0.08%
400,000
-100,000
-20% -$1.14M
ELF icon
65
e.l.f. Beauty
ELF
$5.43B
$4.51M 0.08%
200,000
-50,000
-20% -$1.15M
AXDX
66
DELISTED
Accelerate Diagnostics
AXDX
$4.49M 0.08%
20,000
– –
ACHN
67
DELISTED
Achillion Pharmaceuticals
ACHN
$4.49M 0.08%
+1,000,000
New +$4.44M
IMUX icon
68
Immunic
IMUX
$226M
$4.42M 0.08%
2,188
– –
NTLA icon
69
Intellia Therapeutics
NTLA
$1.66B
$4.35M 0.07%
175,000
-75,000
-30% -$1.41M
ADAP
70
DELISTED
Adaptimmune Therapeutics
ADAP
$4.09M 0.07%
500,000
+200,000
+67% +$1.25M
AKAO
71
DELISTED
Achaogen Inc
AKAO
$3.99M 0.07%
250,000
+50,000
+25% +$951K
CCXI
72
DELISTED
ChemoCentryx, Inc.
CCXI
$3.71M 0.06%
500,000
– –
MGNX icon
73
MacroGenics
MGNX
$259M
$3.7M 0.06%
200,000
-100,000
-33% -$1.73M
LCTX icon
74
Lineage Cell Therapeutics
LCTX
$268M
$3.64M 0.06%
1,465,383
– –
VSTM icon
75
Verastem
VSTM
$604M
$3.52M 0.06%
62,500
+20,833
+50% +$983K
1 2
3
4 5

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q3 2017 Portfolio in Review

As of Q3 2017, Artal Group held 128 positions worth $5.81B, up 1.4% from $5.72B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group withdrew a net $585M in Q3 2017, closing 17 positions and reducing 35 holdings. Its most notable exit was Goldman Sachs, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, Artal Group opened a new position in Achillion Pharmaceuticals worth $4.49M.

  • Artal Group's largest Q3 2017 buy was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M.
  • Artal Group added most to Clovis Oncology, Inc. in Q3 2017, an estimated $7.13M increase.
  • Artal Group's biggest Q3 2017 reduction was Agios Pharmaceuticals, cutting an estimated $15M.
  • Artal Group fully exited Goldman Sachs in Q3 2017, selling an estimated $22.6M.
  • Artal Group's ten largest holdings make up 85% of its $5.81B portfolio in Q3 2017.
  • Artal Group opened 20 new positions and closed 17 in Q3 2017.
  • Artal Group's portfolio value rose 1.4% quarter-over-quarter to $5.81B.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.